227 related articles for article (PubMed ID: 19020004)
1. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.
Savica V; Calò LA; Monardo P; Davis PA; Granata A; Santoro D; Savica R; Musolino R; Comelli MC; Bellinghieri G
J Am Soc Nephrol; 2009 Mar; 20(3):639-44. PubMed ID: 19020004
[TBL] [Abstract][Full Text] [Related]
2. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
3. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
Akizawa T; Tsuruta Y; Okada Y; Miyauchi Y; Suda A; Kasahara H; Sasaki N; Maeda Y; Suzuki T; Matsui N; Niwayama J; Suzuki T; Hara H; Asano Y; Komemushi S; Fukagawa M
BMC Nephrol; 2014 Jun; 15():98. PubMed ID: 24968790
[TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
5. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
[TBL] [Abstract][Full Text] [Related]
6. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.
Block GA; Persky MS; Shamblin BM; Baltazar MF; Singh B; Sharma A; Pergola P; Smits G; Comelli MC
Nephron Clin Pract; 2013; 123(1-2):93-101. PubMed ID: 23797006
[TBL] [Abstract][Full Text] [Related]
7. Salivary phosphorus binding: a novel approach to control hyperphosphatemia.
Eknoyan G
J Am Soc Nephrol; 2009 Mar; 20(3):460-2. PubMed ID: 19244574
[No Abstract] [Full Text] [Related]
8. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
9. What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?
Oh MS; Uribarri J
Clin J Am Soc Nephrol; 2014 May; 9(5):967-70. PubMed ID: 24408115
[TBL] [Abstract][Full Text] [Related]
10. Salivary phosphate secretion in chronic kidney disease.
Savica V; Calò L; Santoro D; Monardo P; Granata A; Bellinghieri G
J Ren Nutr; 2008 Jan; 18(1):87-90. PubMed ID: 18089451
[TBL] [Abstract][Full Text] [Related]
11. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
15. [Salivary phosphate-binding chewing gum--an integrative approach to chronic kidney disease and oral diseases].
Wilczyńska-Borawska M; Borawski J; Stokowska W
Przegl Lek; 2011; 68(9):633-6. PubMed ID: 22335015
[TBL] [Abstract][Full Text] [Related]
16. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
17. A new approach to the evaluation of hyperphosphatemia in chronic kidney disease.
Savica V; Calò LA; Granata A; Caldarera R; Cavaleri A; Santoro D; Monardo P; Savica R; Muraca U; Bellinghieri G
Clin Nephrol; 2007 Oct; 68(4):216-21. PubMed ID: 17969488
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
19. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
